Comparison
While CJC-1295 is used in research to chronically elevate endogenous growth hormone and IGF-1 levels, enabling studies of body composition, metabolic, and anti-aging effects of prolonged GH exposure10, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While CJC-1295 works as a tetrasubstituted 29-amino-acid analog of GHRH(1–29) that acts as a potent agonist at the GHRH receptor and, in its DAC form, covalently binds serum albumin to extend half-life from minutes to days, resulting in sustained pulsatile GH and IGF-1 increase1082, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
CJC-1295 is 29 amino acids long, whereas Semaglutide is longer as it has a length of 31 amino acids. CJC-1295 is made up of a sequence of Tyrosine, Alanine, Aspartic acid, Alanine, Isoleucine, Phenylalanine, Threonine, Glutamine, Serine, Tyrosine, Arginine, Lysine, Valine, Leucine, Alanine, Glutamine, Leucine, Serine, Alanine, Arginine, Lysine, Leucine, Leucine, Glutamine, Aspartic acid, Isoleucine, Leucine, Serine, Arginine. Semaglutide is made up of a sequence of sequence data not available in the current dataset.
CJC-1295
GHRH
Semaglutide
GCG